Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2013

View Archived Issues

MicroRNAs hold promise for regenerating cardiac mass

Oral LM11A-31 shows promise in mouse models of spinal cord injury

[11C]-DED shows potential as a novel imaging tracer in Alzheimer's disease

CEO describes development activity at Synageva BioPharma

Roche and Siena Biotech disclose new BACE inhibitors

Novel tau suppressors prepared at reMYND NV

Tasly Pharmaceutical Group synthesizes new agents for depression

Dezima Pharma in-licenses CETP inhibitor

Olatec begins phase II trial of OLT-1177

U.S. and Korean researchers patent new fusion proteins

Synthon reports early results from its HER2 antibody-drug conjugate

Alnylam Pharmaceuticals divulges novel ribonucleic acids targeting hepcidin

Novartis receives E.U. approval for Bexsero

Omeros reports phase III safety data for OMS-302

BioDelivery Sciences completes BNX safety study

Results reported from pivotal phase III Penthrox trial

Galectin Therapeutics reports preclinical data for GR-MD-02

Ablynx development priorities detailed at J.P. Morgan Healthcare Conference

Replikins reports latest research

Emergent BioSolutions begins phase II study of BioThrax in conjunction with antibiotics

Stealth Peptides reports phase I data for oral Bendavia

Advanced Cell Technology amends protocol for phase I trials in SMD and dry AMD

Progenics acquires Molecular Insight Pharmaceuticals

Domain Therapeutics grants Prexton Therapeutics option to mGlu4 PAMs

Celsion and Zhejiang Hisun Pharmaceutical enter into agreement for ThermoDox

Encouraging results from Nymox's phase III reinjection study of NX-1207

Novartis to return NIC-002 rights to Cytos

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026